Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	ANTUNES Liliana MAZAGATOS Clara MARTÍNEZ-BAZ Iván GOMEZ Verónica MARIA-LOUISE Borg PETROVIĆ Goranka DUFFY Róisín DUFRASNE François E DÜRRWALD Ralf LAZAR Mihaela JANCORIENE Ligita OROSZI Beatrix HUSA Petr HOWARD Jennifer MELO Aryse POZO Francisco PÉREZ-GIMENO Gloria CASTILLA Jesús MACHADO Ausenda DŽIUGYTE Aušra KARABUVA Svjetlana FITZGERALD Margaret FIERENS Sébastien TOLKSDORF Kristin SILVIA-ODETTE Popovici MICKIENE Aukse TÚRI Gergő SOUČKOVÁ Lenka NICOLAY Nathalie ROSE Angela Mc
Year of publication	2024
Type	Article in Periodical
Magazine / Source	EUROSURVEILLANCE
MU Faculty or unit	Faculty of Medicine
Citation
web	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.3.2300708#abstract_content
Doi	http://dx.doi.org/10.2807/1560-7917.ES.2024.29.3.2300708
Keywords	bivalent mRNA COVID-19 vaccines;Omicron XBB lineage-predominant period;VEBIS SARI VE network
Description	We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged???60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated >?6 months before the campaign: from 80% (95%?CI: 50?to?94) for 14–89 days post-vaccination, 15% (95%?CI: -12?to?35) at 90–179 days, and lower to no effect thereafter.
Related projects:	CZECRIN - Czech National Node to the European Clinical Research Infrastructure Network